Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-A[beta] antibody response with Alum to Quil A adjuvant switch

• Published in: Vaccine Vol. 24; no. 13; p. 2275
• Main Authors: Ghochikyan, Anahit, Mkrtichyan, Mikayel, Petrushina, Irina, Movsesyan, Nina, Karapetyan, Adrine, Cribbs, David H, Agadjanyan, Michael G
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 20-03-2006
• Subjects: Alzheimer's disease; Autoimmune diseases; Clinical trials; Dystrophy; Genotype & phenotype; Immune system; Immunization; Immunotherapy; Lymphocytes; Pathology; Peptides; Studies; Vaccines
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2005.11.039

β-Amyloid (Aβ) peptide has been proposed to be a causal factor in Alzheimer's disease (AD). Currently being investigated, active and passive Aβ-immunotherapy significantly reduce Aβ plaque deposition, neuritic dystrophy, and astrogliosis in the brains of APP transgenic (APP/Tg) mice. Immunization with Aβ42formulated in the Th1-type adjuvant QS21 was beneficial for AD patients with significant titers of anti-Aβ antibodies, however, 6% of participants developed meningoencephalitis, likely due to anti-Aβ-specific autoimmune Th1 cells. Thus, successful Aβ vaccination requires the development of strong antibody responses without Th1-type cellular immunity. In this study, we compared the induction of humoral immune responses with Th1-type (Quil A) and Th2-type (Alum) adjuvants singly and in combination, using our novel epitope vaccine composed of self B cell epitope Aβ1-15and foreign T cell epitope PADRE (PADRE-Aβ1-15-MAP). Formulated in Quil A, this vaccine resulted in significantly higher anti-Aβ antibody responses in both BALB/c (H-2d) and C57BL/6 (H-2b) mice, compared with Alum. Anti-Aβ antibodies induced by Alum were predominantly IgG1 type accompanied by lower levels of IgG2a and IgG2b. Quil A induced robust and almost equal titers of anti-Aβ antibodies of IgG1 and IgG2a isotypes and slightly lower levels of IgG2b. Switching adjuvants from Alum to Quil A induced higher concentrations of antibodies than injections with Alum only, however slightly lower than Quil A only. Switching both adjuvants did not change the profile of antibody responses generated by the initial adjuvant injected. These results suggest that switching from Alum to Quil A would be beneficial for AD patients because anti-Aβ antibody production was enhanced without changing the initially generated and likely beneficial Th2-type humoral response.